Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

Nicholas Mitsiades, Constantine Mitsiades, Vassiliki Poulaki et al. · Proceedings of the National Academy of Sciences · 2002 · 748 citations · Full text

Life Sciences, Cell Biology, Oncology +16

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

Sundar Jagannath, Bart Barlogie, James R. Berenson et al. · British Journal of Haematology · 2004 · 740 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

Sundar Jagannath, Brian G.M. Durie, Jeffrey L. Wolf et al. · British Journal of Haematology · 2005 · 399 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies

Robert Z. Orlowski, Peter M. Voorhees, Reynaldo Garcia et al. · Blood · 2004 · 319 citations

Medicine, Oncology, Pharmacology +17

VTD (Velcade, Thalidomide, Dexamethasone) as Primary Therapy for Newly-Diagnosed Multiple Myeloma.

Luhua M. Wang, Donna M. Weber, Kay Delasalle et al. · Blood · 2004 · 48 citations

Medicine, Hematology, Oncology +8